Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries

Standard

Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries. / Seckinger, Anja; Salwender, Hans; Martin, Hans; Scheid, Christof; Hielscher, Thomas; Bertsch, Uta; Hummel, Manuela; Jauch, Anna; Knauf, Wolfgang; Emde-Rajaratnam, Martina; Beck, Susanne; Neben, Kai; Dührig, Jan; Lindemann, Walter; Schmidt-Wolf, Ingo G H; Hänel, Mathias; Blau, Igor W; Weisel, Katja; Weinhold, Niels; Raab, Marc S; Goldschmidt, Hartmut; Choon-Quinones, Mimi; Hose, Dirk.

in: INT J MOL SCI, Jahrgang 25, Nr. 12, 6431, 11.06.2024.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Seckinger, A, Salwender, H, Martin, H, Scheid, C, Hielscher, T, Bertsch, U, Hummel, M, Jauch, A, Knauf, W, Emde-Rajaratnam, M, Beck, S, Neben, K, Dührig, J, Lindemann, W, Schmidt-Wolf, IGH, Hänel, M, Blau, IW, Weisel, K, Weinhold, N, Raab, MS, Goldschmidt, H, Choon-Quinones, M & Hose, D 2024, 'Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries', INT J MOL SCI, Jg. 25, Nr. 12, 6431. https://doi.org/10.3390/ijms25126431

APA

Seckinger, A., Salwender, H., Martin, H., Scheid, C., Hielscher, T., Bertsch, U., Hummel, M., Jauch, A., Knauf, W., Emde-Rajaratnam, M., Beck, S., Neben, K., Dührig, J., Lindemann, W., Schmidt-Wolf, I. G. H., Hänel, M., Blau, I. W., Weisel, K., Weinhold, N., ... Hose, D. (2024). Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries. INT J MOL SCI, 25(12), [6431]. https://doi.org/10.3390/ijms25126431

Vancouver

Bibtex

@article{a65f0b26fecf4a0dbcb3012ca496d721,
title = "Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries",
abstract = "Based on the lack of differences in progression-free and overall survival after a median follow-up of 93 months in our HOVON-65/GMMG-HD4 trial (German part; n = 395) randomizing VAD induction (vincristin/adriamycin/dexamthasone)/tandem-transplantation/thalidomide-maintenance vs. PAD induction (bortezomib/adriamycin/dexamethasone)/tandem transplantation/bortezomib maintenance, we discern how chromosomal aberrations determine long-term prognosis by different patterns of association with proliferation and treatment-dependent response, whether responses achieved by different regimens are equal regarding prognosis, and whether subpopulations of patients could be defined as treatable without upfront {"}novel agents{"} in cases of limited resources, e.g., in low- or middle-income countries. Serum parameters and risk factors were assessed in 395 patients. CD138-purified plasma cells were subjected to fluorescence in situ hybridization (n = 354) and gene expression profiling (n = 204). We found chromosomal aberrations to be associated in four patterns with survival, proliferation, and response: deletion (del) del17p13, del8p21, del13q14, (gain) 1q21+, and translocation t(4;14) (all adverse) associate with higher proliferation. Of these, del17p is associated with an adverse response (pattern 1), and 1q21+, t(4;14), and del13q14 with a treatment-dependent better response (pattern 2). Hyperdiploidy associates with lower proliferation without impacting response or survival (pattern 3). Translocation t(11;14) has no association with survival but a treatment-dependent adverse response (pattern 4). Significantly fewer patients reach a near-complete response or better with {"}conventional{"} (VAD) vs. bortezomib-based treatment after induction or high-dose melphalan. These patients, however, show significantly better median progression-free and overall survival. Molecularly, patients responding to the two regimens differ in gene expression, indicating distinct biological properties of the responding myeloma cells. Patients with normal renal function (89.4%), low cytogenetic risk (72.5%), or low proliferation rate (37.9%) neither benefit in progression-free nor overall survival from bortezomib-based upfront treatment. We conclude that response level, the treatment by which it is achieved, and molecular background determine long-term prognosis. Chromosomal aberrations are associated in four patterns with proliferation and treatment-dependent responses. Associations with faster and deeper responses can be deceptive in the case of prognostically adverse aberrations 1q21+ and t(4;14). Far from advocating a return to {"}outdated{"} treatments, if resources do not permit state-of-the-art-treatment, normal renal function and/or molecular profiling identifies patient subpopulations doing well without upfront {"}novel agents{"}.",
keywords = "Humans, Multiple Myeloma/genetics, Chromosome Aberrations, Female, Male, Middle Aged, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cell Proliferation/drug effects, Prognosis, Adult, Developing Countries, Dexamethasone/therapeutic use, Bortezomib/therapeutic use, Thalidomide/therapeutic use",
author = "Anja Seckinger and Hans Salwender and Hans Martin and Christof Scheid and Thomas Hielscher and Uta Bertsch and Manuela Hummel and Anna Jauch and Wolfgang Knauf and Martina Emde-Rajaratnam and Susanne Beck and Kai Neben and Jan D{\"u}hrig and Walter Lindemann and Schmidt-Wolf, {Ingo G H} and Mathias H{\"a}nel and Blau, {Igor W} and Katja Weisel and Niels Weinhold and Raab, {Marc S} and Hartmut Goldschmidt and Mimi Choon-Quinones and Dirk Hose",
year = "2024",
month = jun,
day = "11",
doi = "10.3390/ijms25126431",
language = "English",
volume = "25",
journal = "INT J MOL SCI",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

RIS

TY - JOUR

T1 - Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries

AU - Seckinger, Anja

AU - Salwender, Hans

AU - Martin, Hans

AU - Scheid, Christof

AU - Hielscher, Thomas

AU - Bertsch, Uta

AU - Hummel, Manuela

AU - Jauch, Anna

AU - Knauf, Wolfgang

AU - Emde-Rajaratnam, Martina

AU - Beck, Susanne

AU - Neben, Kai

AU - Dührig, Jan

AU - Lindemann, Walter

AU - Schmidt-Wolf, Ingo G H

AU - Hänel, Mathias

AU - Blau, Igor W

AU - Weisel, Katja

AU - Weinhold, Niels

AU - Raab, Marc S

AU - Goldschmidt, Hartmut

AU - Choon-Quinones, Mimi

AU - Hose, Dirk

PY - 2024/6/11

Y1 - 2024/6/11

N2 - Based on the lack of differences in progression-free and overall survival after a median follow-up of 93 months in our HOVON-65/GMMG-HD4 trial (German part; n = 395) randomizing VAD induction (vincristin/adriamycin/dexamthasone)/tandem-transplantation/thalidomide-maintenance vs. PAD induction (bortezomib/adriamycin/dexamethasone)/tandem transplantation/bortezomib maintenance, we discern how chromosomal aberrations determine long-term prognosis by different patterns of association with proliferation and treatment-dependent response, whether responses achieved by different regimens are equal regarding prognosis, and whether subpopulations of patients could be defined as treatable without upfront "novel agents" in cases of limited resources, e.g., in low- or middle-income countries. Serum parameters and risk factors were assessed in 395 patients. CD138-purified plasma cells were subjected to fluorescence in situ hybridization (n = 354) and gene expression profiling (n = 204). We found chromosomal aberrations to be associated in four patterns with survival, proliferation, and response: deletion (del) del17p13, del8p21, del13q14, (gain) 1q21+, and translocation t(4;14) (all adverse) associate with higher proliferation. Of these, del17p is associated with an adverse response (pattern 1), and 1q21+, t(4;14), and del13q14 with a treatment-dependent better response (pattern 2). Hyperdiploidy associates with lower proliferation without impacting response or survival (pattern 3). Translocation t(11;14) has no association with survival but a treatment-dependent adverse response (pattern 4). Significantly fewer patients reach a near-complete response or better with "conventional" (VAD) vs. bortezomib-based treatment after induction or high-dose melphalan. These patients, however, show significantly better median progression-free and overall survival. Molecularly, patients responding to the two regimens differ in gene expression, indicating distinct biological properties of the responding myeloma cells. Patients with normal renal function (89.4%), low cytogenetic risk (72.5%), or low proliferation rate (37.9%) neither benefit in progression-free nor overall survival from bortezomib-based upfront treatment. We conclude that response level, the treatment by which it is achieved, and molecular background determine long-term prognosis. Chromosomal aberrations are associated in four patterns with proliferation and treatment-dependent responses. Associations with faster and deeper responses can be deceptive in the case of prognostically adverse aberrations 1q21+ and t(4;14). Far from advocating a return to "outdated" treatments, if resources do not permit state-of-the-art-treatment, normal renal function and/or molecular profiling identifies patient subpopulations doing well without upfront "novel agents".

AB - Based on the lack of differences in progression-free and overall survival after a median follow-up of 93 months in our HOVON-65/GMMG-HD4 trial (German part; n = 395) randomizing VAD induction (vincristin/adriamycin/dexamthasone)/tandem-transplantation/thalidomide-maintenance vs. PAD induction (bortezomib/adriamycin/dexamethasone)/tandem transplantation/bortezomib maintenance, we discern how chromosomal aberrations determine long-term prognosis by different patterns of association with proliferation and treatment-dependent response, whether responses achieved by different regimens are equal regarding prognosis, and whether subpopulations of patients could be defined as treatable without upfront "novel agents" in cases of limited resources, e.g., in low- or middle-income countries. Serum parameters and risk factors were assessed in 395 patients. CD138-purified plasma cells were subjected to fluorescence in situ hybridization (n = 354) and gene expression profiling (n = 204). We found chromosomal aberrations to be associated in four patterns with survival, proliferation, and response: deletion (del) del17p13, del8p21, del13q14, (gain) 1q21+, and translocation t(4;14) (all adverse) associate with higher proliferation. Of these, del17p is associated with an adverse response (pattern 1), and 1q21+, t(4;14), and del13q14 with a treatment-dependent better response (pattern 2). Hyperdiploidy associates with lower proliferation without impacting response or survival (pattern 3). Translocation t(11;14) has no association with survival but a treatment-dependent adverse response (pattern 4). Significantly fewer patients reach a near-complete response or better with "conventional" (VAD) vs. bortezomib-based treatment after induction or high-dose melphalan. These patients, however, show significantly better median progression-free and overall survival. Molecularly, patients responding to the two regimens differ in gene expression, indicating distinct biological properties of the responding myeloma cells. Patients with normal renal function (89.4%), low cytogenetic risk (72.5%), or low proliferation rate (37.9%) neither benefit in progression-free nor overall survival from bortezomib-based upfront treatment. We conclude that response level, the treatment by which it is achieved, and molecular background determine long-term prognosis. Chromosomal aberrations are associated in four patterns with proliferation and treatment-dependent responses. Associations with faster and deeper responses can be deceptive in the case of prognostically adverse aberrations 1q21+ and t(4;14). Far from advocating a return to "outdated" treatments, if resources do not permit state-of-the-art-treatment, normal renal function and/or molecular profiling identifies patient subpopulations doing well without upfront "novel agents".

KW - Humans

KW - Multiple Myeloma/genetics

KW - Chromosome Aberrations

KW - Female

KW - Male

KW - Middle Aged

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Cell Proliferation/drug effects

KW - Prognosis

KW - Adult

KW - Developing Countries

KW - Dexamethasone/therapeutic use

KW - Bortezomib/therapeutic use

KW - Thalidomide/therapeutic use

U2 - 10.3390/ijms25126431

DO - 10.3390/ijms25126431

M3 - SCORING: Journal article

C2 - 38928138

VL - 25

JO - INT J MOL SCI

JF - INT J MOL SCI

SN - 1661-6596

IS - 12

M1 - 6431

ER -